Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Envoy Medical (COCH) Operating Income (2021 - 2026)

Envoy Medical's Operating Income history spans 5 years, with the latest figure at -$6.0 million for Q1 2026.

  • On a quarterly basis, Operating Income fell 16.68% to -$6.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$23.1 million, a 18.7% decrease, with the full-year FY2025 number at -$22.3 million, down 15.65% from a year prior.
  • Operating Income hit -$6.0 million in Q1 2026 for Envoy Medical, up from -$6.4 million in the prior quarter.
  • Over the last five years, Operating Income for COCH hit a ceiling of -$901356.0 in Q2 2022 and a floor of -$6.7 million in Q4 2023.
  • Historically, Operating Income has averaged -$4.3 million across 5 years, with a median of -$4.9 million in 2024.
  • Biggest five-year swings in Operating Income: tumbled 397.03% in 2023 and later skyrocketed 32.34% in 2024.
  • Tracing COCH's Operating Income over 5 years: stood at -$2.9 million in 2022, then crashed by 131.35% to -$6.7 million in 2023, then skyrocketed by 32.34% to -$4.5 million in 2024, then plummeted by 40.36% to -$6.4 million in 2025, then grew by 6.67% to -$6.0 million in 2026.
  • Business Quant data shows Operating Income for COCH at -$6.0 million in Q1 2026, -$6.4 million in Q4 2025, and -$5.7 million in Q3 2025.